Summit Trail Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,422 shares of the medical instruments supplier’s stock after buying an additional 71 shares during the period. Summit Trail Advisors LLC’s holdings in Becton, Dickinson and Company were worth $332,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Gryphon Financial Partners LLC bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $211,000. Congress Wealth Management LLC DE increased its position in Becton, Dickinson and Company by 7.9% during the 4th quarter. Congress Wealth Management LLC DE now owns 1,809 shares of the medical instruments supplier’s stock worth $441,000 after buying an additional 133 shares during the period. Hilltop Holdings Inc. acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $472,000. Peak Asset Management LLC boosted its position in shares of Becton, Dickinson and Company by 4.7% in the fourth quarter. Peak Asset Management LLC now owns 46,842 shares of the medical instruments supplier’s stock valued at $11,421,000 after acquiring an additional 2,122 shares during the period. Finally, Proquility Private Wealth Partners LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at about $205,000. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Stock Performance
Becton, Dickinson and Company stock opened at $234.70 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock has a market cap of $67.83 billion, a PE ratio of 51.70, a P/E/G ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52. The business’s 50-day moving average price is $235.68 and its two-hundred day moving average price is $235.52.
Becton, Dickinson and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.
Analysts Set New Price Targets
Several brokerages have weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Evercore ISI reduced their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $279.50.
Get Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Earnings Per Share Calculator: How to Calculate EPS
- The Average 401k Balance by Age Explained
- Top Stocks Investing in 5G Technology
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.